Stride Pharma Science Q1 Results: Net loss narrows to Rs 163 crore
Revenue from the US business in the June quarter stood at Rs 355.2 crore, up from Rs 301.6 crore last year.Similarly, the company said its revenues from Other Regulated Markets (ORM) was at Rs 304.7 crore in the first quarter of FY23. The same stood at Rs 223.2 crore in the corresponding period last fiscal